AcuityMD has successfully secured $80 million in Series C funding, aiming to enhance its AI-driven platform tailored for the medical device sector.
The investment round, led by StepStone Group with contributions from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management, elevates AcuityMD's valuation to approximately $955 million. With this funding, the company intends to bolster its AI capabilities across sales, leadership, and marketing, refine its MedTech ontology, and expand its platform's functionality to encompass broader product lifecycle workflows.
AcuityMD's platform is already utilized by 16 of the top 20 MedTech firms, helping clients identify over $34 billion in potential opportunities. The company aggregates diverse healthcare datasets into a proprietary ontology, creating a dynamic knowledge graph that connects various healthcare stakeholders and trends. This integration allows commercial teams to access a real-time view of the market, streamlining decision-making processes and enhancing operational efficiency.
With the introduction of AcuityAI, now in open beta, AcuityMD aims to further refine its offerings by providing tailored commercial insights that are often elusive for traditional AI systems. The platform allows sales representatives to focus more on engaging with physicians rather than sifting through fragmented data sources. AcuityMD’s leadership emphasizes that successful AI implementation in healthcare requires a deep understanding of operational workflows, positioning the company for continued growth across the MedTech landscape.